Agonist
Back to library
HealingOral

Larazotide

Also known as: Larazotide Acetate · INN-202 · AT-1001

Synthetic octapeptide tight junction regulator. Antagonizes zonulin signaling to keep intestinal tight junctions closed in response to gluten and other triggers. Studied in celiac disease as adjunctive to a gluten-free diet.

At a glance

Half-life
30 minutes
Common route
Oral
Typical dose range
250–1,000mcg
Stability (reconstituted)
60days refrigerated

Best timing

Oral capsule, taken 15 minutes before meals containing potential triggers. Three times daily in trial protocols.

Contraindications

  • Pregnancy (limited safety data)
  • Active GI infection without diagnosis
  • Known hypersensitivity

Watch symptoms

  • Headache (most common adverse effect in trials)
  • Nasopharyngitis-like symptoms
  • Mild diarrhea or constipation
  • Limited utility outside celiac population without zonulin elevation

Citations

The primary literature.

  1. 01Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet (Phase 3)PubMed
  2. 02Larazotide acetate regulates epithelial tight junctions in vitro and in vivoPubMed
Back to library